Table 2.
Patients’ Characteristics and Their Relation to Tamoxifen Response
| Feature | Refractory (79) | Responders (78) | P-value |
|---|---|---|---|
| Age (years) | |||
| >50 (81) | 41 | 40 | 1 |
| ≤50 (76) | 38 | 38 | |
| Menstrual Status | |||
| Pre (73) | 37 | 36 | 1 |
| Post (84) | 42 | 42 | |
| Histological grade | |||
| II (114) | 57 | 57 | 0.69 |
| III (43) | 22 | 21 | |
| Contraception | |||
| Yes (31) | 14 | 17 | 0.55 |
| No (126) | 65 | 61 | |
| Her-2 status | |||
| +ve (58) | 27 | 31 | 0.51 |
| -ve (99) | 52 | 47 | |
| ER | |||
| +ve (108) | 56 | 52 | 0.61 |
| -ve (49) | 23 | 26 | |
| PR | |||
| +ve (78) | 40 | 38 | 1 |
| -ve (79) | 39 | 40 | |
| Disease site | |||
| Bone only (46) | 15 | 31 | 0.005 |
| Visceral (111) | 64 | 47 | |
| CYP2D6 status | |||
| Mutant (44) | 30 | 14 | 0.027 |
| Wild (113) | 49 | 64 |